The Relationship Between Systemic Inflammatory Index and Other Inflammatory Markers with Clinical Severity of the Disease in Patients with Parkinson’s Disease

<b>Background/Objectives</b>: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra (SN), pathological accumulation of alpha-synuclein, and chronic neuroinflammation. The aim of this study is to evaluate the serum levels of systemic inflammatory markers such as neutrophil-lymphocyte ratio (NLR), neutrophil-HDL ratio (NHR), monocyte-HDL ratio (MHR), platelet-lymphocyte ratio (PLR), IL-6, IGF-1, systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) in patients with PD, and to analyze the relationship between these markers and the clinical stage of the disease as well as its motor and non-motor symptoms. <b>Methods</b>: Fifty-one patients diagnosed with PD and forty-nine HC matched for age and sex were evaluated prospectively. <b>Results</b>: NLR, NHR, and IGF-1 levels were found to be significantly higher in the PD group compared to the HC group (<i>p</i> < 0.05). There was no significant difference between the two groups in terms of PLR, MHR, SII, and SIRI. No significant relationship was found between the inflammatory markers and disease duration, clinical scales, or symptoms. <b>Conclusions</b>: These findings support the role of systemic inflammation in the pathophysiology of PD. Further multi-center, long-term follow-up studies-including simultaneous measurements of central nervous system inflammation markers-are needed for translation into clinical practice.